Literature DB >> 2835949

Factors affecting amplification of BK virus episomal vectors in human cells. Brief report.

M P Grossi1, A Caputo, L Paolini, P G Balboni, G Gerna, M Pagnani, A Corallini, G Barbanti-Brodano.   

Abstract

Analysis of factors determining replication of BK virus (BKV) episomal vectors in human cells showed that vector copy number was related to the level of BKV T antigen expression. T antigen was synthesized efficiently, as assessed by indirect immunofluorescence, in vector-transfected primary embryonic fibroblasts undergoing neoplastic transformation. Surprisingly, transfected continuous cell lines (143 B, HeLa and KB), kept under biochemical selection or tested in transient assays, produced negligible amounts or no T antigen, revealed only by a sensitive ELISA test, suggesting that in these cells vector amplification was under the control of cellular factors. Presence or absence of BKV late region sequences, BKV strain, orientation of the inserted genes and presence or absence of selection were not relevant for vector replication. Type of biochemical selection, however, was important, since BKV vectors containing the thymidine kinase gene replicated better than those containing the neo gene. Despite great variability, vector copy number increased in transfected clones of adenovirus 5-transformed 293 cells, in the absence of immunofluorescence detectable T antigen. These cells express adenovirus immediate early proteins E1A and E1B which may directly or indirectly activate BKV origin of replication.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835949     DOI: 10.1007/BF01311074

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  28 in total

1.  Transformation of mammalian cells with genes from procaryotes and eucaryotes.

Authors:  M Wigler; R Sweet; G K Sim; B Wold; A Pellicer; E Lacy; T Maniatis; S Silverstein; R Axel
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

2.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

3.  The use of drug-resistant markers to study the hybridization of mouse fibroblasts.

Authors:  J W Littlefield
Journal:  Exp Cell Res       Date:  1966-01       Impact factor: 3.905

4.  Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences.

Authors:  M Lusky; M Botchan
Journal:  Nature       Date:  1981-09-03       Impact factor: 49.962

5.  Transcriptional activation of cloned human beta-globin genes by viral immediate-early gene products.

Authors:  M R Green; R Treisman; T Maniatis
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

6.  Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element.

Authors:  M J Imperiale; L T Feldman; J R Nevins
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

Review 7.  Cloning vectors derived from animal viruses.

Authors:  P W Rigby
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

8.  Adenovirus E1A 12S protein induces DNA synthesis and proliferation in primary epithelial cells in both the presence and absence of serum.

Authors:  M P Quinlan; T Grodzicker
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

9.  Simian virus 40 replication in adenovirus-transformed human cells antagonizes gene expression.

Authors:  J S Lebkowski; S Clancy; M P Calos
Journal:  Nature       Date:  1985 Sep 12-18       Impact factor: 49.962

10.  cis and trans activation of globin gene transcription in transient assays.

Authors:  R Treisman; M R Green; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more
  1 in total

1.  New BK virus episomal vector for complementary DNA expression in human cells.

Authors:  M P Grossi; A Caputo; P Rimessi; L Chiccoli; P G Balboni; G Barbanti-Brodano
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.